Equities Analysts Set Expectations for Rezolute Q1 Earnings

Rezolute, Inc. (NASDAQ:RZLT) – Equities researchers at HC Wainwright lowered their Q1 2027 earnings per share (EPS) estimates for Rezolute in a research report issued on Monday, March 30th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($0.18) for the quarter, down from their prior forecast of ($0.08). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Rezolute’s current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Rezolute’s Q2 2027 earnings at ($0.22) EPS, Q3 2027 earnings at ($0.09) EPS, Q4 2027 earnings at ($0.08) EPS and FY2027 earnings at ($0.57) EPS.

RZLT has been the topic of several other reports. Maxim Group set a $4.00 price target on shares of Rezolute in a research report on Friday, December 12th. Jefferies Financial Group restated a “buy” rating and set a $20.00 price objective on shares of Rezolute in a research report on Friday, December 5th. BTIG Research reaffirmed a “buy” rating and issued a $5.00 target price on shares of Rezolute in a research note on Thursday, January 8th. Citizens Jmp cut Rezolute from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 11th. Finally, Guggenheim dropped their price target on Rezolute from $15.00 to $6.00 and set a “buy” rating for the company in a research report on Friday, December 12th. Six investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Rezolute has a consensus rating of “Hold” and a consensus price target of $8.00.

Rezolute Trading Down 0.3%

NASDAQ:RZLT opened at $3.12 on Wednesday. The company has a market capitalization of $298.58 million, a P/E ratio of -3.35 and a beta of 0.65. The firm has a 50-day moving average price of $3.15 and a two-hundred day moving average price of $5.65. Rezolute has a twelve month low of $1.07 and a twelve month high of $11.46.

Rezolute (NASDAQ:RZLT) last released its quarterly earnings data on Thursday, February 12th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.06).

Institutional Investors Weigh In On Rezolute

Hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets acquired a new position in shares of Rezolute in the second quarter valued at approximately $25,000. ExodusPoint Capital Management LP acquired a new stake in Rezolute during the fourth quarter worth approximately $25,000. HB Wealth Management LLC purchased a new stake in Rezolute in the 4th quarter worth approximately $26,000. Fifth Third Wealth Advisors LLC purchased a new stake in Rezolute in the 4th quarter worth approximately $29,000. Finally, Hsbc Holdings PLC purchased a new stake in Rezolute in the 4th quarter worth approximately $29,000. 82.97% of the stock is currently owned by hedge funds and other institutional investors.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.